​

MapLight Therapeutics Ownership | Who Owns MapLight Therapeutics?


OverviewForecastChart

MapLight Therapeutics Ownership Summary


MapLight Therapeutics is owned by 58.29% institutional investors, 53.14% insiders. Novo is the largest institutional shareholder, holding 8.14% of MPLT shares. T. Rowe Price Small-Cap Stock is the top mutual fund, with 1.38% of its assets in MapLight Therapeutics shares.

MPLT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMapLight Therapeutics58.29%53.14%-11.44%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Novo3.69M8.14%$132.13M
Fcpm iii services b.v.3.23M7.13%$115.63M
T. rowe price investment management2.78M6.14%$99.70M
Nan fung group2.30M5.06%$23.44M
Goldman sachs group1.95M4.30%$69.83M
Blackrock funding, inc. /de1.71M3.77%$17.45M
Fmr1.54M3.39%$15.71M
Price t rowe associates inc /md/1.42M3.14%$51.00M
Vanguard group869.67K2.10%$15.28M
5am venture management950.01K2.10%$34.05M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Nan fung group2.30M15.66%$23.44M
Fcpm iii services b.v.3.23M15.41%$115.63M
5am venture management950.01K11.83%$34.05M
Velan capital investment management lp492.89K10.76%$17.67M
Novo3.69M7.67%$132.13M
Superstring capital management lp125.43K2.84%$4.50M
Pivotal bioventure partners investment advisor611.45K2.47%$6.23M
Sanofi912.04K1.48%$9.29M
Dafna capital management171.01K1.17%$6.13M
Blue owl capital lp556.37K1.04%$5.67M

Top Buyers

HolderShares% AssetsChange
Nan fung group2.30M15.66%1.33M
Price t rowe associates inc /md/1.42M0.01%1.31M
Vanguard group869.67K0.00%869.67K
Fmr1.54M0.00%718.38K
Blackrock funding, inc. /de1.71M0.00%687.60K

Top Sellers

HolderShares% AssetsChange
Perceptive advisors---550.00K
State street313.59K0.00%-538.56K
Siren---450.00K
Vestal point capital, lp---420.00K
Vanguard capital management396.08K0.00%-388.07K

New Positions

HolderShares% AssetsChangeValue
Vanguard group869.67K0.00%869.67K$15.28M
Paradigm biocapital advisors lp685.85K0.46%685.85K$24.58M
Boxer capital management75.00K0.20%75.00K$2.69M
Quadrature capital74.48K0.00%74.48K$759.00K
Trexquant investment lp63.79K0.01%63.79K$2.29M

Sold Out

HolderChange
Larson financial group-1.00
True wealth design-3.00
Mai capital management-12.00
Covestor-16.00
Sjs investment consulting-18.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202610934.57%26,392,5746.85%581.96%6229.17%28115.38%
Mar 31, 202628-62.16%2,594,337-88.75%50.19%16-78.38%5-
Dec 31, 202533-8,880,682-21-33---

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price Small-Cap Stock625.05K1.38%-233.00
T. Rowe Price US Small-Cap Core Equity625.05K1.38%-678.00
Vanguard Total Stock Mkt Idx Inv552.28K1.22%73.70K
Vanguard Morn Total Stk Mkt Idx Investor552.28K1.22%73.70K
State Street® SPDR® S&P® Biotech ETF490.72K1.08%1.13K
T. Rowe Price U.S. SC Value Eq Tr-D411.66K0.91%-2.40K
T. Rowe Price Integrated US SmCapGrEq402.79K0.89%402.79K
T. Rowe Price Small-Cap Value493.26K0.89%-
T. Rowe Price New Horizons398.81K0.88%195.20K
US Small-Cap Growth II Equity Comp398.81K0.88%332.41K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 15, 2026Kreitzer Anatol Chief Discovery OfficerSell$96.02K
Oct 15, 2026GILLIS JONATHAN CAO and Interim CFOSell$82.15K
Oct 15, 2026Lillie James Woodruff Chief Scientific OfficerSell$93.03K
Oct 15, 2026Hanson Kristopher General CounselSell$72.88K
Oct 15, 2026Foff Erin Pennock Chief Medical OfficerSell$124.07K

Insider Transactions Trends


DateBuySell
2026 Q4-6
2026 Q3746
2026 Q2--

MPLT Ownership FAQ


Who Owns MapLight Therapeutics?

MapLight Therapeutics shareholders are primarily institutional investors at 58.29%, followed by 53.14% insiders and -11.43% retail investors. The average institutional ownership in MapLight Therapeutics's industry, Biotech Stocks , is 385.89%, which MapLight Therapeutics falls below.

Who owns the most shares of MapLight Therapeutics?

MapLight Therapeutics’s largest shareholders are Novo (3.69M shares, 8.14%), Fcpm iii services b.v. (3.23M shares, 7.13%), and T. rowe price investment management (2.78M shares, 6.14%). Together, they hold 21.41% of MapLight Therapeutics’s total shares outstanding.

Does Blackrock own MapLight Therapeutics?

BlackRock is not among the top 10 institutional shareholders of MapLight Therapeutics.

Who is MapLight Therapeutics’s biggest shareholder by percentage of total assets invested?

Nan fung group is MapLight Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.66% of its assets in 2.3M MapLight Therapeutics shares, valued at 23.44M$.

Who is the top mutual fund holder of MapLight Therapeutics shares?

T. Rowe Price Small-Cap Stock is the top mutual fund holder of MapLight Therapeutics shares, with 1.38% of its total shares outstanding invested in 625.05K MapLight Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools